<qa>  What is the purpose of the trial?The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir DTG containing regimen in HIV-1 infected, antiretroviral therapy ART-experienced adults with current or historical failure on an integrase inhibitor INI containing regimen. The study will assess DTG 50mg twice daily administered initially with the current failing ART regimen but then with an optimised background ART regimen OBR after Day 7. The first analyses will be conducted after the last subject enrolled has completed 24 weeks. Subjects may remain on study after Week 24. 